Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.
about
Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligandsMicrofluidic enrichment for the single cell analysis of circulating tumor cells.Molecular pathology of lung cancer: key to personalized medicine.TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-JunSequential activation of Elk-1/Egr-1/GADD45α by arsenicLoss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cellsModeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expressionReduced expression levels of PTEN are associated with decreased sensitivity of HCC827 cells to icotinib.Antitumor activity of high-dose pulsatile gefitinib in non-small-cell lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.[Sequence-dependent effect of docetaxel with gefitinib on the proliferation and apoptosis of lung adenocarcinoma cell H1975].PTEN Tumor Suppressor Network in PI3K-Akt Pathway ControlRedundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cellsAbility of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer.Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo.miR-205 regulates A549 cells proliferation by targeting PTEN.Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib.Sarcomatous transformation of EGFR and TP53 mutation-positive metastatic adenocarcinoma of the lungs, masquerading as a primary pleomorphic sarcoma of the proximal femur.miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance.Subsequent treatment of epidermal growth factor receptor-tyrosine kinase inhibitor failure in patients with advanced lung adenocarcinomaOncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancerMolecular mechanisms contributing to resistance to tyrosine kinase-targeted therapy for non-small cell lung cancerDrug Resistance to EGFR Inhibitors in Lung CancerElevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancerEGFR inhibition in non-small cell lung cancer: current evidence and future directionsEGFR protein expression using a specific intracellular domain antibody and PTEN and clinical outcomes in squamous cell lung cancer patients with EGFR-tyrosine kinase inhibitor therapy.Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.Paradoxical induction of growth arrest and apoptosis by EGF via the up-regulation of PTEN by activating Redox factor-1/Egr-1 in human lung cancer cells.BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations.Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients.Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance.Current and future molecular diagnostics in non-small-cell lung cancer.PTEN and PI3K/AKT in non-small-cell lung cancer.Phosphatase and tensin homolog deleted on chromosome 10 degradation induced by NEDD4 promotes acquired erlotinib resistance in non-small-cell lung cancer.A genetic interaction analysis identifies cancer drivers that modify EGFR dependency.FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor.Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.EB-virus latent membrane protein 1 potentiates the stemness of nasopharyngeal carcinoma via preferential activation of PI3K/AKT pathway by a positive feedback loop.
P2860
Q26829104-F98055D2-2C3D-4BE8-BA14-C6207206B15BQ27340255-1DCECA4D-9F36-4706-AB6C-D9DAD314B399Q27691299-4E6CC338-50B8-4B3C-9539-78800C98B40CQ27853317-4A9D919C-09F4-440E-AC3C-6AF44CAA3E25Q28391425-61A07517-01B7-481A-B921-20EC86A5C928Q28481370-91395A67-3E19-411C-8F3E-F49801052BCDQ28484612-7D82D8E5-99F8-431D-BDA8-4CA9DDDC54ACQ33684793-F9EE0758-D321-441F-8CC2-4E0D26BE67A5Q33744196-B4FF8A4F-13CC-4454-9169-97FE673D1FE3Q34201724-BD62C638-19D5-4C95-8D3E-5832806FD7FEQ34202681-16980426-C206-49B7-8C5C-1E86A72734C4Q34704781-94369FDD-CC78-4720-80E8-19741B4117AFQ34852951-CAD8DF35-A866-4791-85C2-21DD283522C7Q35081010-D1C20D23-5834-44FA-B84D-3DD7AB992321Q35117568-25D01F87-8AAF-453C-8C78-DE012F21BFC9Q35152542-562D09D8-30DF-4B23-BA7F-AEBE0FBDFEA8Q35406639-B7B3CAEA-7CFE-4FF6-8407-23F389A480ACQ35602423-769B2739-A8A2-4922-94A3-E4BC967C3E10Q35632411-E3A39F0F-C682-4E19-AA23-C9672CF009BDQ36093612-F4B67995-AB16-4803-A73D-6514A1E9CC0DQ36247850-424130FB-714D-4CB3-9592-BF467180333AQ36801144-51BC43ED-0352-4DD8-99FE-C0E761D4148AQ36814305-3F7904D1-2337-4C05-B47F-6C737707DAA5Q36834883-512E6AC6-F276-4CB9-A71B-72FEC7519A99Q37099888-051F32F0-16FD-41F2-AB54-CB2B9F5EB6C4Q37180302-27C073EF-E6C5-465D-BE7A-CE63A05352EDQ37204247-C88D1745-A13D-4119-A2CA-A4BD03E8B8D6Q37211974-1433EF68-E29F-4194-A393-2F780F45990FQ37706156-6D6BBFBD-A857-4329-81FE-3BAA9F7D7DA2Q37708873-C684D284-C402-4BD5-B7E5-0C7A776C6427Q38021967-7340FEE1-CCB2-492E-921E-CF56211C39B4Q38390044-E217D3E9-8A0A-48C1-B3B5-0F58750ECDA9Q38504491-CD02303E-D942-4CC5-ACCB-293E1708FDBAQ38543780-43E50883-0FAA-4B63-8E81-1E8AC725D7F2Q38629644-CD1C7A17-021B-401C-9841-ABA12147E771Q38697136-88BF626E-4682-40EC-82D4-3E6E1EC4A427Q38717620-134BC39A-C684-4070-B01F-7E5B2FEEE073Q38966912-0967C265-B9C9-4C36-B03F-8F24FCBDA87CQ39124519-9D129D11-E07B-482E-A06C-4F55759E7115Q41122951-BCCAD491-1E72-41B6-8CAD-7303300AB31F
P2860
Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Loss of PTEN expression by blo ...... receptor-activating mutations.
@en
Loss of PTEN expression by blo ...... receptor-activating mutations.
@nl
type
label
Loss of PTEN expression by blo ...... receptor-activating mutations.
@en
Loss of PTEN expression by blo ...... receptor-activating mutations.
@nl
prefLabel
Loss of PTEN expression by blo ...... receptor-activating mutations.
@en
Loss of PTEN expression by blo ...... receptor-activating mutations.
@nl
P2093
P1433
P1476
Loss of PTEN expression by blo ...... receptor-activating mutations.
@en
P2093
Akihiko Kawahara
Chizuko Yamamoto
Hidetaka Uramoto
Hiroto Izumi
Kazutaka Nakashima
Kimitoshi Kohno
Kosei Yasumoto
Masayoshi Kage
Mayumi Ono
Michihiko Kuwano
P304
P356
10.1158/0008-5472.CAN-10-0043
P407
P577
2010-10-19T00:00:00Z